Litigation Details for SUN PHARMA GLOBAL FZE v. LUPIN LIMITED (D.N.J. 2018)
✉ Email this page to a colleague
SUN PHARMA GLOBAL FZE v. LUPIN LIMITED (D.N.J. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-02-14 |
| Court | District Court, D. New Jersey | Date Terminated | 2021-09-30 |
| Cause | 15:1126 Patent Infringement | Assigned To | Freda L. Wolfson |
| Jury Demand | Both | Referred To | Tonianne J. Bongiovanni |
| Parties | SUN PHARMACEUTICAL INDUSTRIES, INC. | ||
| Patents | 8,778,999 | ||
| Attorneys | GENE Y. KANG | ||
| Firms | Rivkin Radler LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in SUN PHARMA GLOBAL FZE v. LUPIN LIMITED
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for SUN PHARMA GLOBAL FZE v. LUPIN LIMITED (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-03-07 | 185 | Opinion | associated with cataract surgery. See U.S. Patent No. 8,778,999; Compl., Ex. A. Defendants, …pH of about 7.4 to about 8.5.” See U.S. Patent No. 8,778,999; Compl., Ex. A. …substantive patent law, see ECF No. 121, at 11-12, defects, errors, and omissions in the patent application…8, the motivations of the patent examiner, id. at 8-9, whether the patent examiner reviewed Bowman I…anticipated” Plaintiffs’ patent, id. at 13- 16, and whether Plaintiffs’ patent is “obvious” in light of | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
